388 related articles for article (PubMed ID: 12556239)
1. Tuberous sclerosis: from tubers to mTOR.
Kwiatkowski DJ
Ann Hum Genet; 2003 Jan; 67(Pt 1):87-96. PubMed ID: 12556239
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
[TBL] [Abstract][Full Text] [Related]
3. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.
Kwiatkowski DJ
Cancer Biol Ther; 2003; 2(5):471-6. PubMed ID: 14614311
[TBL] [Abstract][Full Text] [Related]
4. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.
Inoki K; Li Y; Zhu T; Wu J; Guan KL
Nat Cell Biol; 2002 Sep; 4(9):648-57. PubMed ID: 12172553
[TBL] [Abstract][Full Text] [Related]
5. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
Tee AR; Fingar DC; Manning BD; Kwiatkowski DJ; Cantley LC; Blenis J
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13571-6. PubMed ID: 12271141
[TBL] [Abstract][Full Text] [Related]
6. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity.
Li Y; Inoki K; Guan KL
Mol Cell Biol; 2004 Sep; 24(18):7965-75. PubMed ID: 15340059
[TBL] [Abstract][Full Text] [Related]
8. Tumour suppressors hamartin and tuberin: intracellular signalling.
Krymskaya VP
Cell Signal; 2003 Aug; 15(8):729-39. PubMed ID: 12781866
[TBL] [Abstract][Full Text] [Related]
9. TSC1 and TSC2: genes that are mutated in the human genetic disorder tuberous sclerosis.
Sampson JR
Biochem Soc Trans; 2003 Jun; 31(Pt 3):592-6. PubMed ID: 12773162
[TBL] [Abstract][Full Text] [Related]
10. The tuberous sclerosis complex genes in tumor development.
Mak BC; Yeung RS
Cancer Invest; 2004; 22(4):588-603. PubMed ID: 15565817
[TBL] [Abstract][Full Text] [Related]
11. Regulation of tuberous sclerosis complex (TSC) function by 14-3-3 proteins.
Nellist M; Goedbloed MA; Halley DJ
Biochem Soc Trans; 2003 Jun; 31(Pt 3):587-91. PubMed ID: 12773161
[TBL] [Abstract][Full Text] [Related]
12. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
Roux PP; Ballif BA; Anjum R; Gygi SP; Blenis J
Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13489-94. PubMed ID: 15342917
[TBL] [Abstract][Full Text] [Related]
13. United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling.
Manning BD; Cantley LC
Biochem Soc Trans; 2003 Jun; 31(Pt 3):573-8. PubMed ID: 12773158
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathogenesis of tuber formation in tuberous sclerosis complex.
Crino PB
J Child Neurol; 2004 Sep; 19(9):716-25. PubMed ID: 15563019
[TBL] [Abstract][Full Text] [Related]
15. Missense mutations to the TSC1 gene cause tuberous sclerosis complex.
Nellist M; van den Heuvel D; Schluep D; Exalto C; Goedbloed M; Maat-Kievit A; van Essen T; van Spaendonck-Zwarts K; Jansen F; Helderman P; Bartalini G; Vierimaa O; Penttinen M; van den Ende J; van den Ouweland A; Halley D
Eur J Hum Genet; 2009 Mar; 17(3):319-28. PubMed ID: 18830229
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
17. A large deletion in TSC2 causes tuberous sclerosis complex by dysregulating PI3K/AKT/mTOR signaling pathway.
Fu J; Liang P; Zheng Y; Xu C; Xiong F; Yang F
Gene; 2024 May; 909():148312. PubMed ID: 38412945
[TBL] [Abstract][Full Text] [Related]
18. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products.
van Slegtenhorst M; Nellist M; Nagelkerken B; Cheadle J; Snell R; van den Ouweland A; Reuser A; Sampson J; Halley D; van der Sluijs P
Hum Mol Genet; 1998 Jun; 7(6):1053-7. PubMed ID: 9580671
[TBL] [Abstract][Full Text] [Related]
19. The tuberous sclerosis complex.
Orlova KA; Crino PB
Ann N Y Acad Sci; 2010 Jan; 1184():87-105. PubMed ID: 20146692
[TBL] [Abstract][Full Text] [Related]
20. Tuberous sclerosis complex: from Drosophila to human disease.
Pan D; Dong J; Zhang Y; Gao X
Trends Cell Biol; 2004 Feb; 14(2):78-85. PubMed ID: 15102439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
